Full Recourse Note. (a) The first clause of Section 1 of the Full Recourse Note shall be amended and restated in its entirety to read as follows: “If the Holder has not converted the outstanding principal hereunder into Preferred Stock in accordance with Section 3 hereof by the date which is the earlier of (i) the first anniversary after the first Regulatory Approval (as defined below) and (ii) September 30, 2008 (the “Maturity Date”),” (b) The first proviso of Section 1 of the Full Recourse Note shall be amended to replace the reference to “the Committee (as defined in the License Agreement)” with “the Board of Directors of the Company”. (c) The following proviso shall be inserted at the end of the first sentence of Section 1 of the Full Promissory Note, immediately prior to the definition of “Regulatory Approval”: “; provided further, however, if no Regulatory Approval has been received on or prior to the Maturity Date, the Company shall have the right to extend the Maturity Date by six month periods (each, an “Extension Period”) by delivery of a written notice to the Holder certifying that it is the reasonable, good faith belief, after due diligence and inquiry by the Company’s Board of Directors, of the Company that such Regulatory Approval is likely to be obtained in a timely manner (each, an “Extension Notice”), at least 30 days prior to the Maturity Date or the then current Extension Period, as the case may be.” (d) Section 5.6 of the Full Recourse Note is hereby deleted and replaced in its entirety to read as follows:
Appears in 3 contracts
Sources: Securities Amendment Agreement (Acorda Therapeutics Inc), Securities Amendment Agreement (Acorda Therapeutics Inc), Securities Amendment Agreement (Acorda Therapeutics Inc)